Distinct Patient, Tumour, Treatment Characteristics and a Different Pattern and Risk of Survival Events Over Time Between Young BRCA1/2 Carriers By Ogkologos - March 10, 2025 804 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a global cohort of patients harbouring germline pathogenic/likely pathogenic variants in BRCA1 or BRCA2 Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR New Blood Test Can Screen For Over 50 Cancers June 7, 2021 FDA Approves Erdafitinib for Locally Advanced or Metastatic Urothelial Carcinoma February 2, 2024 Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities March 6, 2026 Oncofertility: Creating a Bridge Between Cancer Care and Reproductive Health December 23, 2019 Load more HOT NEWS What could DeepMind ‘solving’ the protein folding problem mean for cancer... For AYAs with Advanced Cancer, Study Finds Serious Communication Gaps about... ctDNA May Guide Who Needs Chemo After Colorectal Cancer Surgery Five Questions With…Jessica, Katie, and Melanie